ACIP evidence to recommendations for use of of an additional COVID-19 vaccine dose in immunocompromised people

Details

• Corporate Authors:
  National Center for Immunization and Respiratory Diseases (U.S.)
• Description:
  The emergence of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), has led to a global pandemic with substantial societal and economic impacts on individual persons and communities. In the United States, more than 45 million cases and more than 700,000 COVID-19-associated deaths have been reported as of October 20, 2021. Persons of all ages are at risk for infection and severe disease. However, the risk for severe illness from COVID-19 is higher in people who are immunocompromised.
• Subjects:
  Coronavirus Infections/prevention & Control COVID-19 Vaccines COVID-19/prevention & Control Guidelines As Topic Immunization, Secondary Immunocompromised Host
• Document Type:
  Webpage
• Name as Subject:
  Pfizer-BioNTech COVID-19 vaccine ; COMIRNATY ; Johnson & Johnson’s Janssen COVID-19 vaccine ; Moderna COVID-19 vaccine ; United States. Advisory Committee on Immunization Practices.
• Collection(s):
  Stephen B. Thacker CDC Library
• Main Document Checksum:
  urn:sha256:1c23064eb4b9cd07ac5b032f8a899d10cfd6b1c938040980d41a7dcdaacb19c8
• Download URL:
  https://stacks.cdc.gov/view/cdc/111169/cdc_111169_DS1.pdf
• File Type:
  [PDF - 774.71 KB ]